TIDMRXB
Rex Bionics PLC
18 November 2016
Rex Bionics Plc
("Rex Bionics" or the "Company")
Presentation of REX Case Report at Spinal Cord Injury
Conference
-- First evidence from multiple sessions of exercises with REX
-- Significant reduction in pain
18th November 2016: Rex Bionics Plc (AIM: RXB), the pioneer of
the REX Robot technology that enhances the mobility of wheelchair
users, is pleased to announce the findings of a case report
presented at the annual meeting of the Australian & New Zealand
Spinal Cord Society, "ANZCoS", (Adelaide, Australia; 16-18
November, 2016).
Gilly Davy, Senior Neurological Physiotherapist and Clinical
Director of Connect Neuro Physiotherapy, Auckland, New Zealand
presented her evaluation of the practical clinical use of the REX,
utilising the dynamic exercise treatment branded as "REXercises",
by reference to a case report.
The participant, a 35-year-old male, had a complete T5 spinal
cord injury from a traumatic accident in 2006. He has been living
an independent lifestyle from his wheelchair since then but has
suffered with chronic right shoulder, neck and thoracic spine pain
with intermittent headaches for the past two years.
The participant completed once a week exercise regime in the REX
over a 10 week period. The results demonstrated a significant
improvement - with a complete resolution of headaches and neck pain
and a significant reduction in shoulder and thoracic pain. The
Numeric Pain Rating (NPR) scale improved significantly - with
"current pain" reducing from 4/10 to 2/10 and "worst pain" reducing
from 9/10 to 4/10.
Significant improvement was also recorded in The Goal Attainment
Score (GAS) and the Canadian Occupational Performance Measure
(COPM) - see "Further Data" below.
Up to 80% of people living with a spinal cord injury suffer from
shoulder, neck and back pain.
Gilly Davy's presentation concluded "Standing, while completing
upper body rehabilitation and strengthening in a stand-alone
robotic exercise device, can significantly enhance neck and
shoulder pain management and improve quality of life - highlighting
that robotic exercise devices can offer a range of rehabilitation
opportunities."
Crispin Simon, Chief Executive of Rex Bionics commented: "This
case report is the first time that the results of a comprehensive,
multi-week programme of REX treatment have been presented at a
scientific conference; and is in line with the feedback that we get
from patients - that exercising with REX can offer reduced pain and
improved sleep."
A copy of this announcement has been posted on the Company's
website at www.rexbionics.com/.
For further information please contact:
Rex Bionics Plc
Crispin Simon, Chief Executive Officer
+44 (0) 7483167 851
Peter Worrall, Chief Financial Officer
+44 (0)1428 645416
Stifel Nicolaus Europe Limited (NOMAD and Broker)
Jonathan Senior/ Stewart Wallace / Ben Maddison
+44 (0) 20 7710 7600
Consilium Strategic Communications
Mary-Jane Elliott / Chris Welsh
rexbionics@consilium-comms.com
+44 (0) 203 709 5700
Further Notes
The Goal Attainment Score uses a scale of -2 (deteriorated from
base level), through 0 (goal achieved per expectations), to +2
(goal achieved above expectations). The following scores were
recorded for the four goals. Reduce pain between the shoulders: +1;
Reduce headaches: +2; Strengthen shoulders: 0; Improve sitting
posture: 0.
The Canadian Occupational Performance Measured recorded
achievement of the goal to "sleep through the night without waking
up with pins and needles in arms and shoulders", on scales of
satisfaction and performance with a maximum of 10 each. The score
in this case report increased from 6 out of 20 (3 + 3), to 20 out
of 20 (10 + 10).
Note: The Case Report participant is an employee of Rex
Bionics.
About Rex Bionics Plc
Rex Bionics is the pioneer of the "REX" that provides robotic
standing, walking and exercise support for wheelchair users; and
was founded by two British engineers with first-hand experience of
the needs of wheelchair users. REX is used by people who have
suffered a spinal cord injury, stroke or other traumatic brain
injury; and people with multiple sclerosis, muscular dystrophy and
cerebral palsy.
We are working with physiotherapists to develop the concept and
practice of Robot-Assisted Physiotherapy (RAP); and also offer REX
P, for use in the home, enabling customers to walk and stand with
their hands free - providing more work and recreation options.
Wheelchair users are at risk of developing numerous medical
complications from extended periods of sitting. By enabling them to
spend more time standing, walking and exercising, REX may offer
significant health benefits, including improved sleep and
maintenance of joint range, and a reduction in spasm, pain, common
abdominal problems and prescription drug use.
Our commitment to engineering excellence is complemented by a
commitment to clinical science and the RAPPER II clinical trial
results show high levels of practicality, safety and user
enthusiasm.
Our Vision is that every day, around the world, thousands of
people get relief with REX, from the harm - the pain, discomfort
and inconvenience - of neurological accidents and illnesses; and
that many will be cured.
Rex Bionics was admitted to trading on the London Stock
Exchange's AIM in 2014. REX is not registered for At-Home use in
the United States of America.
Enquiries to (info@rexbionics.com)
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFEDLVLDLIR
(END) Dow Jones Newswires
November 18, 2016 02:01 ET (07:01 GMT)
Rex Bionics (LSE:RXB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rex Bionics (LSE:RXB)
Historical Stock Chart
From Sep 2023 to Sep 2024